From Discovery to Delivery: Charting Progress in Gynecologic Oncology

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilcon Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Rebecca Porter, MD, PhD, physician, Dana-Farber Cancer Institute, assistant professor, medicine, Harvard Medical School

Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD

ByUrsula A. Matulonis, MD,Rebecca L. Porter, MD, PhD

January 28th 2026

Drs Matulonis and Porter discuss the role of immunotherapy in gynecologic cancer management, focusing on clinical breakthroughs and future directions.

Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD

ByUrsula A. Matulonis, MD,Panagiotis A. Konstantinopoulos, MD, PhD

December 11th 2025

Drs Matulonis and Konstantinopoulos discuss the different subtypes of endometrial cancer and treatment developments for this disease.

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

ByUrsula A. Matulonis, MD,Taymaa May, MD, MSc

November 13th 2025

In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD

Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

Five Under 5: Top Oncology Videos for the Week of 1/25

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma